Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India.

ABSTRACT:

Background

Over the years, there has been introduction of newer drugs, like bendamustine and ibrutinib, for the management of chronic lymphocytic leukaemia (CLL). Though these drugs lead to better survival, they are also associated with higher cost. The existing evidence on cost effectiveness of these drugs is from high-income countries, which has limited generalisability for low-income and middle-income counties. Therefore, the present study was undertaken to assess the cost-effectiveness of three therapeutic regimens, chlorambucil plus prednisolone (CP), bendamustine plus rituximab (BR) and ibrutinib for CLL treatment in India.

Methods

A Markov model was developed for estimating lifetime costs and consequences in a hypothetical cohort of 1000 CLL patients following treatme

SUBMITTER: Nehra P 

PROVIDER: S-EPMC10305972 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature